Felker, G. M., Butler, J., Ibrahim, N. E., Piña, I. L., Maisel, A., Bapat, D., … PROVE-HF Investigators. (2021). Implantable Cardioverter-Defibrillator Eligibility After Initiation of Sacubitril/Valsartan in Chronic Heart Failure: Insights From PROVE-HF. Circulation, 144(2), 180–182. https://doi.org/10.1161/CIRCULATIONAHA.121.054034

Felker, G Michael, Javed Butler, Nasiren E. Ibrahim, Ileana L. Piña, Alan Maisel, Devavrat Bapat, Alexander Camacho, et al. “Implantable Cardioverter-Defibrillator Eligibility After Initiation of Sacubitril/Valsartan in Chronic Heart Failure: Insights From PROVE-HF.” Circulation 144, no. 2 (July 13, 2021): 180–82. https://doi.org/10.1161/CIRCULATIONAHA.121.054034.

Felker GM, Butler J, Ibrahim NE, Piña IL, Maisel A, Bapat D, et al. Implantable Cardioverter-Defibrillator Eligibility After Initiation of Sacubitril/Valsartan in Chronic Heart Failure: Insights From PROVE-HF. Circulation. 2021 Jul 13;144(2):180–2.

Felker, G. Michael, et al. “Implantable Cardioverter-Defibrillator Eligibility After Initiation of Sacubitril/Valsartan in Chronic Heart Failure: Insights From PROVE-HF.” Circulation, vol. 144, no. 2, July 2021, pp. 180–82. Pubmed, doi:10.1161/CIRCULATIONAHA.121.054034.

Felker GM, Butler J, Ibrahim NE, Piña IL, Maisel A, Bapat D, Camacho A, Ward JH, Williamson KM, Solomon SD, Januzzi JL, PROVE-HF Investigators. Implantable Cardioverter-Defibrillator Eligibility After Initiation of Sacubitril/Valsartan in Chronic Heart Failure: Insights From PROVE-HF. Circulation. 2021 Jul 13;144(2):180–182.